Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-α for the treatment of renal cell carcinoma (RCC), at the American Association for Cancer Research Annual Meeting 2016 (AACR16), in New Orleans. ARC-HIF2 is Arrowhead’s first RNAi therapeutic program to target tissues outside the liver.
The poster titled, “Novel HIF-2α targeted RNAi therapeutic for renal cell carcinoma” (abstract 2064), describes data from various stages of development of ARC-HIF2, including RNAi trigger selection, HIF2-α target validation, delivery and targeting ligand validation, and multiple RCC tumor models. These data show that important advancements are being made in this program and for Arrowhead’s Dynamic PolyconjugateTM (DPCTM) delivery platform generally, including the following key findings:
- Proof-of-concept ligand dependent, functional delivery was demonstrated using the DPC targeted delivery platform
- Silencing HIF2-α expression by RNA interference resulted in reduction of HIF-2α regulated genes
- In two different RCC tumor bearing mouse models, ARC-HIF2 inhibited tumor growth and promoted tumor cell death and structural degeneration (Original Source)
Shares of Arrowhead are currently trading at $6.39, up $0.16 or 2.57%. ARWR has a 1-year high of $9.36 and a 1-year low of $3.07. The stock’s 50-day moving average is $4.77 and its 200-day moving average is $5.00.
On the ratings front, Arrowhead has been the subject of a number of recent research reports. In a report issued on March 31, Jefferies Co. analyst Eun Yang reiterated a Hold rating on ARWR, with a price target of $4, which implies a downside of 35.3% from current levels. Separately, on February 10, Piper Jaffray’s Edward Tenthoff maintained a Buy rating on the stock and has a price target of $13.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Edward Tenthoff have a total average return of -4.0% and -4.1% respectively. Yang has a success rate of 54.5% and is ranked #3375 out of 3795 analysts, while Tenthoff has a success rate of 33.6% and is ranked #3408.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.